At Evolve, we understand that intellectual property assessment is a crucial component of investment decision-making in the life sciences sector. Our specialised investor services provide you with clear, actionable insights into the strength, scope, and competitive positioning of potential investments’ IP portfolios.
We offer comprehensive IP landscape analysis to identify potential risks and opportunities within your target investment areas. Our experienced attorneys can evaluate the quality and durability of patent protection, assess freedom-to-operate concerns, and identify potential challenges that could impact valuations. By leveraging our deep scientific expertise and commercial insight, we help you make informed investment decisions with confidence.
Strategic IP assessment
Our team provides detailed analysis of IP assets to inform your investment. We conduct thorough evaluations of patent portfolios, examining critical factors such as claim scope, territorial coverage, patent term, and resilience against potential challenges. Our assessments provide insights into how the IP aligns with market opportunities and competitive dynamics, helping you identify both risks and hidden value.
Due diligence support
For investors conducting due diligence, we deliver clear, comprehensive IP analysis that highlights strengths and potential risks. We can assess the alignment between the company’s IP strategy and its business objectives, evaluate the robustness of its freedom-to-operate position, and identify opportunities to strengthen protection. Our attorneys have extensive experience communicating complex IP matters in terms that resonate with business leaders and stakeholders, ensuring you receive practical insights that support your decision-making process.
Fractional IP counsel
Why fractional IP counsel for investors? Portfolio companies often lack senior IP leadership at the moments that matter most for your investment. Our fractional IP counsel model places a named senior patent attorney inside the company’s team, giving you confidence that the IP is being actively managed. When an asset is acquired, we can support the new acquisition on an interim or permanent basis, bringing the IP portfolio into line with your commercial priorities and handling the day-to-day IP needs. Our patent directors bring the real-world industry experience that you only get working in-house, reporting IP risks and opportunities clearly to the board and to you. Our own AI tools, developed by our attorneys specifically for pharma and biotech IP, including Cassandra for due diligence, let us review target portfolios, prior art and competitor filings faster and in more depth, while our attorneys make the judgement calls. This gives you a depth that a lone consultant cannot offer and an in-house perspective that a traditional IP firm rarely has, with a global strategic approach across your portfolio.
Read more
